ReviewInfectious agents and cancer2025
Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.
Review in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
- Parasite in cancer therapy: molecular mechanisms and translational potential.Frontiers in immunology · 2026Review
- Parasites' immunomodulators: a breakthrough in immunotherapeutics displaying antineoplastic activity against human colorectal and hepatocellular carcinoma cells.Infectious agents and cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer research is constantly evolving to yield successful innovations. A plethora of pre-clinical studies have illustrated the promising potential utility of parasites and parasite-derived molecules in cancer therapy. In this review, we underscore, for the first time, the possible multifaceted applications of parasites in the field of oncology, aiming to draw attention to the vital role of parasite-derived cancer therapy and offer novel insights for the evolution of advanced cancer therapeutics. Several studies have demonstrated that parasites offer a variety of strategies for cancer therapy. These include acting as immunotherapeutics such as cancer vaccines, therapeutic antibodies, adjuvants, immunomodulators, oncolytic agents, and NF-κB inhibitors. Additionally, they can be utilized in targeted therapy, gene therapy, and in combination with current cancer treatments to synergistically enhance their effectiveness. A notable strategy is parasites' ability to overcome tumor resistance to chemotherapy, a significant obstacle in cancer therapy. There is still much to explore about parasite-based anti-cancer therapies. With further research and the translation of parasitological discoveries into effective cancer interventions, parasites may hold the key to effectively treat cancer in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.